Technology | ECG Monitoring Services | November 19, 2015

iRhythm Technologies Launches New iOS App for Reporting Irregular Heartbeat Symptoms

Application complements ZIO continuous cardiac monitoring service to provide physicians more complete picture of patient health

iRhythm Technologies, ZIO continuous cardiac monitoring service, myZIO app, irregular heartbeat symptoms, reporting

Image courtesy of iRhythm Technologies

November 19, 2015 — iRhythm Technologies Inc. announced the launch of new patient engagement tools to enhance the diagnosis of cardiac arrhythmias. Patients using the ZIO continuous cardiac monitoring service from iRhythm can now conveniently log heart symptoms with the new myZIO app for iPhone or at myZIO.com.

This new family of smartphone and Web applications is designed to provide additional data for physicians to help rule-in or rule-out arrhythmias sooner in the diagnostic pathway – and adjust the patient's care accordingly.

In addition to allowing patients to digitally record any irregular heartbeat symptoms and associated activities, the myZIO app maximizes a patient's experience with the ZIO Service by providing education, reminders, answering common questions and offering recommendations on the use of the ZIO Patch. Information from the app provides physicians with a more complete picture of the patient's health, allowing for faster and more accurate diagnosis and potentially eliminating the need for additional testing.

Each year, millions of patients see physicians because they feel symptoms that may be caused by an irregular heartbeat, or arrhythmia. The iRhythm ZIO Service allows physicians to diagnose arrhythmias more definitively than via previously available diagnostic technologies, according to iRhythm.

The ZIO Service has the ability to record, store and analyze every heartbeat for up to 14 days, well beyond the 48-hour window of Holter monitoring. Studies of patients wearing the ZIO Patch documented that 50 percent of arrhythmias were diagnosed after 48 hours and that 75 percent of atrial fibrillation patients experienced their longest episode after 48 hours.

"The myZIO app is a great companion to iRhythm's continuous cardiac monitoring service, making it even easier for my patients with suspected cardiac arrhythmias to record their symptoms while wearing the ZIO Patch," said R. Hardwin Mead, M.D., partner and co-founder at Silicon Valley Cardiology in East Palo Alto, Calif. "Such a discreet and convenient way to track symptoms gets the patient intimately involved in the diagnostic process. Combining that additional valuable information with the 20,000 minutes of heartbeat data captured by the ZIO Patch will provide me an even more robust clinical arrhythmia interpretation."

The myZIO iOS app is available for download from the Apple App Store. myZIO is also available as a web application for non-iPhone users at myZIO.com.

For more information: www.irhythmtech.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init